STOCK TITAN

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Geron (Nasdaq: GERN) granted stock options covering 150,000 common shares to three new employees as a hiring inducement, effective November 17, 2026.

The options have a $1.00-per-share exercise price, equal to Geron’s closing share price on the grant date, and a ten-year term. They vest over four years, with 12.5% vesting six months after each employee starts and the rest vesting in equal installments of whole shares over the following 42 months. Vesting requires continued employment through each applicable vesting date.

Loading...
Loading translation...

Positive

  • None.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Options on 150,000 common shares at $1.00 per share could dilute existing holders if exercised.

Key Figures

Options granted: 150,000 options Exercise price: $1.00 per share Option term: 10 years +3 more
Options granted
150,000 options
Granted to three newly hired employees
Exercise price
$1.00 per share
Equal to the closing price on the grant date
Option term
10 years
Term of the stock options
Vesting period
4 years
Subject to continued employment
Initial vesting
12.5%
Vests on the six-month anniversary of employment commencement
Remaining vesting period
42 months
Remaining shares vest in equal installments

Key Terms

nasdaq listing rule 5635(c)(4)
1 terms
nasdaq listing rule 5635(c)(4) regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FOSTER CITY, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective November 17, 2026, it granted stock options to purchase an aggregate of 150,000 shares of common stock to three newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.00 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.

The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.

About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.

CONTACT:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares do Geron’s November 17, 2026 inducement options cover, and what is the exercise price?

Geron granted options to buy 150,000 common shares at $1.00 per share to three newly hired employees. The exercise price matched Geron’s closing share price on the grant date.

What plan governs Geron’s November 17, 2026 inducement option grants?

The options are subject to Geron’s 2018 Inducement Award Plan and the form of stock option agreement under that plan. The board’s Compensation Committee granted the awards under Nasdaq Listing Rule 5635(c)(4).

Keep reading